Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Human second-trimester fetal liver-derived mesenchymal stromal cells are more effective than adult bone marrow MSCs for their superior growth kinetics, immunomodulatory, and osteogenic potential.

Kumar A., Ramesh S., Kumar V., Mathews JE., Madhuri V.

Laboratory Study on Immune Modulation, published in Tissue Cell (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Tissue Cell (2025)
Country
Scotland
Reported sample size
—
Source database
PubMed
PMID
40101501
DOI
10.1016/j.tice.2025.102859

Abstract (original English)

Mesenchymal stromal cells (MSCs) are promising candidates for cell therapy. Most of the therapeutic applications have used adult bone marrow MSCs, adipose MSCs and perinatal tissue-derived MSCs. Recent evidence suggests that MSCs from mid-gestational fetal tissues are more primitive, grow faster and are biologically more closely related to embryonic stem cells than other sources of MSCs. However, the expression of pluripotency genes raises the question of whether these genes are safe for clinical application. In this study, we demonstrated that second-trimester fetal liver-derived MSCs lack the expression of pluripotent markers and maintain their proliferative and osteogenic differentiation potential beyond passage 12. Compared to other sources, FL-MSCs exhibit characteristics that are promising for use in skeletal regeneration. MSCs were isolated from the second-trimester fetal liver and characterized for surface antigen expression, pluripotency marker expression and multilineage differentiation. The growth kinetics, population doubling, and number of colony-forming units were analyzed at the 3rd, 5th, 8th and 10th passages of FLMSCs and compared with those of BMMSCs. The immunomodulatory properties of FLMSCs were analyzed by a T-cell proliferation assay. The osteogenic differentiation potential of FL-MSCs was assessed at passages 3, 5, 8 and 12 and compared with that of BMMSC

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsHumansOsteogenesisFemaleCell DifferentiationCell ProliferationPregnancyPregnancy Trimester, SecondLiverAdult

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research